Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 4Terminated 3Not yet recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Colorectal Neoplasms 17Stomach Neoplasms 14Rectal Neoplasms 10Pancreatic Neoplasms 7Colonic Neoplasms 6Biliary Tract Neoplasms 5Adenocarcinoma 4HER2-positive Gastric Cancer 3Esophageal Neoplasms 3Cholangiocarcinoma 3Ovarian Neoplasms 2Neoplasms 2Lymphoma, Extranodal NK-T-Cell 2Locally Advanced Gastric Cancer 2Cirrhosis, Familial, with Pulmonary Hypertension 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Spinocerebellar Degenerations 1Rectal Neoplasms Malignant 1Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Neoadjuvant Chemotherapy 1MSI-H Colorectal Cancer 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1Locally Advanced Low Rectal Adenocarcinoma 1

Interventions

selinexor 3pegaspargase 3Oxaliplatin 2Gemcitabine 2tislelizumab 1sugemalimab 1Thiotepa 1Radiotherapy 1Immune Checkpoint Inhibitors 1Azacitidine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Extranodal NK-T-Cell × Oxaliplatin × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07554482 2026-04-28

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Beijing Tongren Hospital

Phase 2 Not yet recruiting
34 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡